Company intelligence / Profile preview
Synedgen
Claremont, California, United Statessynedgen.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Synedgen’s lead program MIIST305 has shown preclinical efficacy in mitigating GI acute radiation syndrome injury in animal models. The company has received significant federal funding to advance this candidate through proof-of-concept studies toward FDA approval. Its wound care portfolio includes two commercialized products with strong safety profiles supported by DoD grants
- Therapeutic areas
- GastroenterologyPulmonologyOphthalmologyDermatologyInfectious Diseases
- Modalities
- Proprietary polysaccharide derivativesglycochemistry-based therapeuticstopical and oral formulations
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
BARDA/U.S. Department of Health & Human Services Biomedical Advanced Research and Development Authority ($119 million contract)U.S. ArmyDARPA support for product development/grants
Beyond the preview
Go deeper on Synedgen.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Synedgen.